Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis

Area of Science:

• Immunology
• Neuroscience
• Genetics

Background:

• Cytokines play a role in multiple sclerosis (MS) pathogenesis, but their specific involvement in primary progressive MS (PPMS) remains unclear.
• Understanding these molecular differences is crucial for developing targeted therapies for distinct MS subtypes.

Purpose of the Study:

• To investigate and compare the mRNA expression profiles of various cytokines and their receptors in white blood cells across different MS clinical subtypes: relapsing-remitting (RRMS), secondary progressive (SPMS), and PPMS.
• To identify unique molecular signatures associated with PPMS pathogenesis.

Main Methods:

• A cross-sectional study design was employed.
• Quantitative analysis of mRNA expression levels for IL-18, IL-12p35, IL-12p40, TNF-alpha, IFN-gamma, IL-10, IL-4, TGF-beta, IL-12Rbeta1, and IL-12Rbeta2 in unstimulated white blood cells.
• Comparison of gene expression patterns between MS subtypes (RRMS, SPMS, PPMS) and healthy controls.

Main Results:

• All MS subtypes exhibited distinct mRNA expression patterns compared to healthy controls.
• RRMS and SPMS patients showed elevated IL-12p40, IL-18, and TGF-beta mRNA levels relative to controls.
• PPMS patients uniquely displayed increased IL-18 mRNA and decreased IL-12Rbeta1 mRNA, alongside decreased IFN-gamma and IL-10 mRNA compared to RRMS and controls.

Conclusions:

• Cytokine and cytokine receptor mRNA profiles can effectively differentiate between various clinical subtypes of MS.
• The findings suggest that distinct cytokine pathways are implicated in the pathogenesis of PPMS compared to RRMS and SPMS.
• These unique molecular signatures in PPMS warrant further investigation for potential therapeutic targets.